Reishi Mushroom and Cortisol: What the Research Actually Says About Stress Hormones

Every week a patient sits down in my office and asks some version of the same question: "My cortisol is through the roof — is there anything natural I can take?" And every week I have to give the same honest, mildly unsatisfying answer: it depends on what you mean by "high cortisol," and the evidence for most natural cortisol-lowering supplements is thinner than the brochure suggests.

Reishi mushroom (Ganoderma lucidum) is consistently at the top of that conversation. It has a 2,000-year track record in Traditional Chinese Medicine as a tonic for the spirit — lingzhi, the "mushroom of immortality" — and the modern supplement industry has latched onto that reputation enthusiastically. A Google search for "reishi cortisol" returns thousands of articles promising dramatic hormone rebalancing. The reality, as revealed by actual clinical trials, is considerably more measured.

Here is what I can tell you, honestly, as of mid-2026.

Why Cortisol Even Matters

Cortisol is your primary glucocorticoid stress hormone, produced by the adrenal cortex in response to signals from the hypothalamus and pituitary — a chain of command called the HPA (hypothalamic-pituitary-adrenal) axis. In short bursts, cortisol is your friend: it mobilizes glucose, sharpens focus, and gets you out of trouble. The problem is when modern life keeps the tap running.

Chronically elevated cortisol is associated with disrupted sleep, weight gain around the midsection, immune suppression, impaired memory consolidation, and mood disorders. It also feeds back on the HPA axis itself, eventually leading to dysregulation — the mechanism behind what integrative practitioners call "adrenal fatigue," a term that is not an official medical diagnosis but does point at something real in terms of HPA dysfunction.

So when someone tells you a supplement can lower cortisol, they are making a claim about a very specific, tightly regulated hormonal system. That claim deserves scrutiny.

The Biology: How Reishi Might Interact With the HPA Axis

Reishi contains two major categories of bioactive compounds: polysaccharides (primarily beta-glucans) and triterpenes (ganoderic acids, lucidenic acids). Both have been studied in preclinical models.

The triterpenes are the most pharmacologically interesting for stress modulation. Ganoderic acids share a structural similarity with steroid hormones and have demonstrated activity at glucocorticoid receptors in cell culture studies. In animal models, reishi extracts have blunted corticosterone spikes (corticosterone is the rodent equivalent of human cortisol) under acute stress conditions. The proposed mechanisms include modulation of the HPA axis at the level of the hypothalamus, and direct antioxidant effects that reduce oxidative stress-driven cortisol release.

Beta-glucans, meanwhile, are best known for their immunomodulatory effects — they interact with dectin-1 and toll-like receptors on immune cells — but there is emerging evidence they may also influence the gut-brain axis, which has bidirectional communication with the HPA axis.

All of that is genuinely interesting biology. The question is whether it translates into measurable cortisol changes in actual humans taking capsules. That is where we have to slow down.

What Controlled Trials Actually Show

A 2024 Adaptogenic Mushroom Blend Trial

The most relevant recent human data comes from a randomized, double-blind, placebo-controlled trial published in 2025 (PMID: 41540766; DOI: 10.1002/brb3.71193). Fifty adults aged 22–55 with moderate-to-severe stress symptoms were assigned to either a proprietary mushroom blend capsule or placebo for 12 weeks. The blend — called Restake — contained five mushrooms at standardized >30% beta-glucan potency: Hericium erinaceus (Lion's Mane), Cordyceps militaris, Ganoderma lucidum (Reishi), Lentinula edodes (Shiitake), and Grifola frondosa (Maitake).

The results were encouraging:

Those are statistically significant findings with consistent directionality across multiple outcomes. The study was well-designed, and the effect sizes on anxiety and sleep are clinically meaningful. I would normally be fairly enthusiastic about this — except for one important caveat.

This was a five-mushroom blend, not reishi alone. We cannot isolate reishi's contribution from Lion's Mane (which has its own NGF-promoting and anxiolytic properties), Cordyceps (energy and VO2 max effects), or the other species. The 5.5% cortisol reduction is real, but we do not know how much of it, if any, was driven specifically by the reishi component. The study authors themselves do not attempt to disentangle individual species contributions.

A Systematic Review of Ganoderma lucidum Trials

For a broader view specifically on reishi, a 2025 systematic review and meta-analysis (PMID: 40510787; DOI: 10.1002/fsn3.70423) pooled 17 randomized controlled trials with 971 participants conducted between 2004 and 2024. This is the most comprehensive synthesis of the reishi-only literature to date, and the findings deserve careful reading.

On the positive side, the meta-analysis found statistically significant effects on:

• Body mass index (reduced by 0.43 kg/m²)
• Creatinine (reduced by 0.14 mg/dL)
• Glutathione peroxidase activity (increased by 2.29 U/g Hb — an antioxidant marker)
• Resting heart rate (reduced by 3.92 bpm)

The reduction in heart rate is interesting from a stress-physiology standpoint — the autonomic nervous system and HPA axis are deeply intertwined, and lower resting heart rate often reflects reduced sympathetic tone. But on the outcomes you might most care about — inflammatory markers, blood pressure, lipid profile, fasting glucose — there were no significant effects.

And here is the sobering methodological note: the authors rated the quality of evidence as "very low" across all outcomes using GRADE methodology, and 16 of 17 included studies received "Poor" quality ratings. Doses varied wildly from 200 mg to 11,200 mg per day, intervention durations ranged from 1 to 24 weeks, and populations were heterogeneous. Drawing firm clinical conclusions from this body of research would be premature — and intellectually dishonest.

The Gulf War Illness Caution

I want to mention one more study because it illustrates something important: dose and population context matter enormously. A placebo-controlled crossover trial (PMID: 33915962; DOI: 10.3390/ijerph18073671) tested reishi in 25 men with Gulf War Illness, a condition characterized by chronic fatigue, pain, and cognitive symptoms. The results for reishi were mixed at best — and at higher doses, overall symptom severity actually worsened significantly (p=0.012).

Why? We do not know for certain. It could reflect immune overstimulation in a population with pre-existing inflammatory dysregulation, or interactions with the specific symptom cluster present in GWI. But the lesson is clear: "it's natural" does not mean "more is better" or "safe for everyone." Reishi is a pharmacologically active substance.

Putting It in Context: What We Know and What We Do Not

Here is my honest clinical summary:

• Reishi probably has some adaptogenic activity. The preclinical biology is plausible, the traditional use is longstanding, and the multi-mushroom RCT showed real cortisol and stress signal improvements.
• We cannot confirm reishi alone is the driver. No adequately powered, well-conducted trial has isolated reishi's cortisol effects in humans. The systematic review found reishi studies to be mostly low quality.
• The magnitude of effect is modest. A 5.5% cortisol reduction is real but not transformative. If your cortisol is 25 mcg/dL when it should be 10, no mushroom supplement is correcting that. You need a proper endocrinology workup.
• Higher doses are not necessarily better. The Gulf War Illness data is a reminder that dose-response relationships for immune-active compounds can be non-linear or even negative in certain populations.
• The evidence quality is low. The GRADE assessment of "very low" across 17 trials is a red flag. We need larger, better-controlled, longer-duration studies focused specifically on HPA axis outcomes.

Who Might Reasonably Try Reishi for Stress?

Given all of that, here is how I think about reishi as part of a stress-management conversation with patients:

Reishi is a reasonable adjunct for otherwise healthy adults experiencing chronic low-grade psychological stress who want to try a safe, low-risk supplement while maintaining realistic expectations. The safety profile is good — well-tolerated at standard doses (typically 1–3 g daily of fruiting body extract), with mild GI upset being the most common side effect. Occasional reports of liver toxicity exist at very high doses, so I advise against exceeding 6 g/day and recommend a break if you develop jaundice or RUQ discomfort (seek care immediately if that happens).

I am more cautious in patients with autoimmune conditions, those on immunosuppressive therapy, or anyone with a complex inflammatory disease — the immunomodulatory activity cuts both ways.

What reishi is not: a substitute for treating the root cause of stress. Sleep hygiene, exercise, evidence-based psychotherapy, and addressing lifestyle contributors to chronic stress have far larger effect sizes in the literature than any supplement. Reishi belongs in the "reasonable supporting role" category, not as a lead actor.

A Note on Product Quality

If you do try reishi, the fruiting-body-vs-mycelium debate matters here more than with some other mushrooms. Triterpenes — the compounds most plausibly linked to HPA modulation — are concentrated in the fruiting body. Mycelium-on-grain products often have low triterpene content and high starch content. Look for products with a Certificate of Analysis showing beta-glucan percentage (aim for ≥20–30% from a reputable third-party lab) and ideally some triterpene quantification. The dose used in most studies that showed effects was 1,500–3,000 mg of standardized extract daily.

Frequently Asked Questions

Can reishi actually lower my cortisol levels?

Possibly, modestly. The best human evidence — a 2025 randomized controlled trial — found a 5.5% reduction in serum cortisol after 12 weeks of an adaptogenic mushroom blend that included reishi. However, that blend contained four other mushrooms, so we cannot attribute the effect to reishi alone. Reishi-only clinical trials on cortisol specifically are limited and methodologically weak. I would describe the current evidence as "suggestive but unconfirmed" rather than "proven."

How long does it take for reishi to help with stress?

Based on available trial data, meaningful effects on subjective stress and anxiety markers started appearing at 4–8 weeks and were most pronounced at 12 weeks. This is consistent with how adaptogenic herbs and mushrooms generally work — they are not acute interventions. Do not expect to pop a reishi capsule before a stressful meeting and feel calmer. This is a weeks-to-months commitment if you want to assess whether it helps you.

Is it safe to take reishi every day long-term?

At standard doses (1–3 g daily of fruiting body extract), reishi appears to be safe for most healthy adults based on available trial data — the 12-week RCT mentioned above found no adverse effects at those doses. Long-term safety data beyond 6 months is limited, so I generally suggest periodic breaks (e.g., 8 weeks on, 2 weeks off) until we have more data. People with autoimmune conditions, bleeding disorders, or those on blood thinners or immunosuppressants should consult their physician before starting. And if you are pregnant or breastfeeding, skip it — we simply do not have safety data in those populations.